Skip to main content
H

HEXIMA LIMITED. — Investor Relations & Filings

Ticker · HXL ISIN · AU0000111932 ASX Professional, scientific and technical activities
Filings indexed 244 across all filing types
Latest filing 2023-09-06 Regulatory Filings
Country AU Australia
Listing ASX HXL

About HEXIMA LIMITED.

https://hexima.com.au/

Hexima Limited focuses on the research and development of plant-derived proteins for human therapeutic applications. The company's primary development candidate is pezadeftide (HXM163), a proprietary plant defensin formulated as a topical treatment for onychomycosis, a fungal nail infection. Pezadeftide is engineered to penetrate the nail plate and target underlying fungal pathogens. The company's technology platform utilizes the natural defense mechanisms of plants to develop novel antimicrobial and antifungal treatments. Originally focused on agricultural biotechnology, the company transitioned to human health to address unmet needs in dermatology. Its activities involve the clinical evaluation of protein-based therapies designed to offer improved efficacy and safety profiles compared to existing antifungal treatments.

Recent filings

Filing Released Lang Actions
Final Director's Interest Notice - Michael Aldridge 2 pages 177.7KB
Regulatory Filings
2023-09-06 English
Final Director's Interest Notice - Scott Robertson 2 pages 178.8KB
Regulatory Filings
2023-09-06 English
Final Director's Interest Notice - Jake Nunn 2 pages 179.4KB
Regulatory Filings
2023-09-06 English
Initial Director's Interest Notice - Geoffrey Kempler 3 pages 173.6KB
Regulatory Filings
2023-09-06 English
Board Restructure 3 pages 124.9KB
Regulatory Filings
2023-09-05 English
Appendix 4E 2 pages 296.8KB
Regulatory Filings
2023-08-30 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.